# Potent, Selective Pyrrolopyrimidine PDE11A4 Inhibitors with Improved Pharmaceutical Properties

## TL;DR

Researchers developed a new PDE11A4 inhibitor with better solubility and effectiveness for potential therapeutic use.

## Contribution

A novel pyrrolopyrimidine PDE11A4 inhibitor with improved pharmaceutical properties and potency was developed.

## Key findings

- The compound shows potent and selective inhibition of PDE11A4.
- It has improved aqueous solubility compared to previous compounds.
- The inhibitor demonstrates promising activity in cell-based models.

## Abstract

Previous work demonstrated
target engagement with an orally bioavailable,
potent, selective PDE11A4 inhibitor in the mouse hypothalamus. This
compound was limited by low aqueous solubility, stimulating the need
for alternative leads with improved pharmaceutical properties to carry
out efficacy studies. This paper outlines optimization of a pyrrolopyrimidine
hit leading to a potent, selective PDE11A4 inhibitor with improved
pharmaceutical properties and promising activity in cell-based models
of enzyme activity.